In phase II clinical trials, dovitinib prolonged DCR and median PFS from 3% and 5.5 months to 25% and 10.9 months in patients with FGFR1‐amplified/HR‐positive breast cancer, respectively.151. This evidence concerns the gene FGFR1 and breast carcinoma.